Eli Lilly’s Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling Novo Nordisk’s Ozempic. The company plans to submit Phase-III trial data to regulators by year-end, anticipating approvals from 2026.

In April 2025, results from a Phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill, injectable dulaglutide or a placebo daily for 40 weeks showed that orforglipron produced a reduction in blood glucose levels by 1.3 to 1.6 percentage points from a starting level of 8%.